2025
In the time of COVID-19: challenges, successes and lessons learned from studies in cancer patients
Mack P, Crawford J, Chang A, Yin A, Klein S, Shea P, Hirsch F, Zidar D, Simon V, Gleason C, McBride R, Cordon-Cardo C, VanOudenhove J, Halene S, Lee F, Mantis N, Kushi L, Weiskopf D, Merchant A, Reckamp K, Skarbinski J, Figueiredo J. In the time of COVID-19: challenges, successes and lessons learned from studies in cancer patients. Journal Of The National Cancer Institute 2025, djaf073. PMID: 40127178, DOI: 10.1093/jnci/djaf073.Peer-Reviewed Original ResearchChanging public health landscapePublic health landscapeEnrollment of participantsSARS-CoV-2National Cancer InstituteRisk of SARS-CoV-2 infectionU.S. National Cancer InstituteNational Institute of AllergyOverall healthHealth landscapeSelf-reportCohort studyStudy designBiospecimen collectionInstitute of AllergySARS-CoV-2 infectionCancer InstituteStandard serological testsData elementsStudy immune responsesHematologic malignanciesClinicopathological dataNational InstituteCancer patientsCOVID-19Cardiovascular Risk Factors in Myeloproliferative Neoplasms: Associations with Survival and Thrombotic Outcomes
How J, Leiva O, Redd R, Marneth A, DeAngelo D, Dieli-Conwright C, El-Jawahri A, Kamaz B, Kim C, Lindsley C, Luskin M, Stahl M, Wazir M, Weeks L, Hobbs G. Cardiovascular Risk Factors in Myeloproliferative Neoplasms: Associations with Survival and Thrombotic Outcomes. Blood Vessels Thrombosis & Hemostasis 2025, 100051. DOI: 10.1016/j.bvth.2025.100051.Peer-Reviewed Original ResearchMyeloproliferative neoplasm patientsCardiovascular risk factorsEssential thrombocythemiaMyeloproliferative neoplasmsPolycythemia veraThrombotic outcomesThrombotic riskRisk factorsDiagnosis of hematological malignanciesMyeloproliferative neoplasm subtypeIncreased risk of deathType 2 diabetes mellitusMyeloproliferative neoplasms diagnosisRetrospective cohort analysisSex-matched controlsManaging cardiovascular risk factorsAssociated with survivalImprove patient morbidityRisk of deathMF patientsHematologic malignanciesMPN diagnosisPatient morbidityDana-FarberArterial/venous thrombosis
2024
Mitochondrial heteroplasmy improves risk prediction for myeloid neoplasms
Hong Y, Pasca S, Shi W, Puiu D, Lake N, Lek M, Ru M, Grove M, Prizment A, Joshu C, Platz E, Guallar E, Arking D, Gondek L. Mitochondrial heteroplasmy improves risk prediction for myeloid neoplasms. Nature Communications 2024, 15: 10133. PMID: 39578475, PMCID: PMC11584845, DOI: 10.1038/s41467-024-54443-3.Peer-Reviewed Original ResearchConceptsClonal hematopoiesis of indeterminate potentialClonal hematopoiesisVariant allele fractionHeteroplasmic variantsIndeterminate potentialMyeloid neoplasmsHeteroplasmyMultiple mutationsAllele fractionMutationsHigh-risk groupPathogenic risk factorsMarkersRisk score modelDeleteriousnessSpliceosomeHematologic malignanciesRisk stratificationNeoplasm developmentNeoplasmsNeoplasm incidenceRisk factorsVariantsIdentifying Patients with Erythrocytosis Not Requiring JAK2 Testing: External Validation and Decision Analysis of the Jakpot Prediction Rule
Lam B, Ito S, Ryu J, O'Sullivan K, Potnis K, Lu R, Bidikian A, Freed J, La J, Goshua G. Identifying Patients with Erythrocytosis Not Requiring JAK2 Testing: External Validation and Decision Analysis of the Jakpot Prediction Rule. Blood 2024, 144: 3669-3669. DOI: 10.1182/blood-2024-198033.Peer-Reviewed Original ResearchNegative predictive valueBeth Israel Deaconess Medical CenterClinical prediction rulePolycythemia veraIncremental net monetary benefitHealth resource utilizationPV patientsMyeloproliferative neoplasmsVA cohortTest characteristicsUS health system perspectivePrediction ruleAssociated with increased riskNon-fatal cardiovascular eventsExternal validation cohortAssociated with increased risk of strokeRandomized trial dataMarkov cohort modelLifetime time horizonProbabilistic sensitivity analysesRisk of strokePersistent erythrocytosisMedian ageHematologic malignanciesDiagnostic workupSex, Race and Geographic Disparities in Early Age at Onset Hematologic Malignancies
Sklarz T, DuBois T, Lynch S. Sex, Race and Geographic Disparities in Early Age at Onset Hematologic Malignancies. Blood 2024, 144: 5117. DOI: 10.1182/blood-2024-207878.Peer-Reviewed Original ResearchNon-Hispanic blacksIncidence rate ratiosNon-Hispanic whitesNon-Hispanic Black individualsLate-onset diseaseNational Program of Cancer RegistriesNon-Hispanic Asian/Pacific IslanderPrevention effortsRelative riskNon-Hispanic white populationPrecision public healthPublic health approachSurveillance dataOnset diseaseEarly-onset cancersHigh-burden statesPopulation-level surveillance dataNon-Hodgkin's lymphomaHighest incidence rateHematologic malignanciesHigher relative riskScreening interventionsCancer RegistryRacial/ethnic subpopulationsNon-HispanicTargeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions
Bidikian A, Bewersdorf J, Shallis R, Getz T, Stempel J, Kewan T, Stahl M, Zeidan A. Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions. Expert Review Of Anticancer Therapy 2024, 24: 1131-1146. PMID: 39367718, DOI: 10.1080/14737140.2024.2414071.Peer-Reviewed Original ResearchErythropoiesis-stimulating agentsTargeted therapyLR-MDSHR-MDSHypoxia-inducible factorAllogeneic hematopoietic stem cell transplantationLandscape of targeted therapiesHematopoietic stem cell transplantationHeterogeneous group of hematologic malignanciesGroup of hematologic malignanciesMolecular prognostic toolsDuration of responseStem cell transplantationTrial designClinical trial designHypomethylating agentsCell transplantationHematologic malignanciesImprove patient outcomesRNA splicing machineryImmune evasionPrognostic toolTGF-betaTherapyEffective treatmentSplicing the Difference: Harnessing the Complexity of the Transcriptome in Hematopoiesis
Maul-Newby H, Halene S. Splicing the Difference: Harnessing the Complexity of the Transcriptome in Hematopoiesis. Experimental Hematology 2024, 140: 104655. PMID: 39393608, PMCID: PMC11732257, DOI: 10.1016/j.exphem.2024.104655.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAlternative splicingAlternative splicing eventsStem cell maintenanceSplicing factor mutationsHematopoietic stem cell maintenanceExpression of beta-globinField of stem cell researchSplicing eventsSplicing factorsFunctional blood cellsAberrant splicingStudy of hematopoiesisComplex regulationCell maintenanceSplicingCellular differentiationBeta-globinMyelodysplastic syndromeMyeloid malignanciesHematologic malignanciesStem cell researchCell sortingMutationsTranscriptomeAberrant expressionModern Photon-Based Craniospinal Irradiation in Leptomeningeal Disease
Keit E, Peterson J, Johnstone P, Robinson T, Figura N. Modern Photon-Based Craniospinal Irradiation in Leptomeningeal Disease. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e242. DOI: 10.1016/j.ijrobp.2024.07.542.Peer-Reviewed Original ResearchIntensity modulated radiotherapyCraniospinal irradiationLeptomeningeal diseaseHematologic malignanciesSolid tumorsOverall survivalProton therapyLocal failureAssociated with improved OSDelay systemic therapyG3+ toxicitySymptomatic leptomeningeal diseaseSite of spreadKaplan Meier methodPhoton-based treatmentsPrimary cancer typeAcute gradeG3 fatigueMedian OSModulated radiotherapyNeutropenic feverMedian followPalliative radiotherapyDisseminated diseaseSystemic therapyALL-408 Unveiling the Shadows: Thiamine Deficiency Manifesting As Sudden-Onset Blindness in a Patient With Leukemia
Ramachandran S, Stempel J, Podoltsev N, Mahajan A. ALL-408 Unveiling the Shadows: Thiamine Deficiency Manifesting As Sudden-Onset Blindness in a Patient With Leukemia. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s268. DOI: 10.1016/s2152-2650(24)01106-6.Peer-Reviewed Original ResearchWernicke's encephalopathyThiamine deficiencyB-ALLHematologic malignanciesDiagnostic challengePhiladelphia chromosome-positive B-cell acute lymphoblastic leukemiaB-cell acute lymphoblastic leukemiaTreated with hyper-CVADHigh index of suspicionPrevent permanent neurological damageDasatinib dose reductionSudden onset blindnessIndex of suspicionAcute lymphoblastic leukemiaLoss of vibratory sensationPh+ B-ALLCerebrospinal fluid analysisSevere neurological dysfunctionCancer-directed therapyPermanent neurological damageVitamin B1 levelsAtypical neurological findingsHyper-CVADOphthalmologic examBilateral blindnessUtility and Outcomes of Ovarian Tissue Cryopreservation and Transplantation for Gynecologic Cancers
Erden M, Gayete-Lafuente S, Vural N, Oktay K. Utility and Outcomes of Ovarian Tissue Cryopreservation and Transplantation for Gynecologic Cancers. Obstetrics And Gynecology 2024, 144: 481-492. PMID: 39173181, PMCID: PMC11499045, DOI: 10.1097/aog.0000000000005708.Peer-Reviewed Original ResearchCryopreserved ovarian tissue transplantationOvarian tissue cryopreservationOvarian tissue transplantationTissue cryopreservationAutologous transplantationGynecologic cancerTissue transplantationOutcome of autologous transplantationPreserving ovarian functionCochrane Library databasesOvarian endocrine functionPooled-effect estimatesSystematic reviewRisk-of-bias assessmentOvarian stimulationHematologic malignanciesLonger-term outcomesFertility preservationOvarian functionBreast cancerLibrary databasesTransplantationGraft longevityCancerEndocrine functionCAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cellular & Molecular Immunology 2024, 21: 1089-1108. PMID: 39134804, PMCID: PMC11442786, DOI: 10.1038/s41423-024-01207-0.Peer-Reviewed Original ResearchCAR-natural killerCAR-T cellsCAR-TSolid tumorsHematologic malignanciesCell therapyChimeric antigen receptor (CAR)-T cell therapyImmuno-suppressive tumor microenvironmentCAR-T cell therapyCellular cancer immunotherapyRelapsed/refractory hematologic malignanciesCAR-NK cellsTumor traffickingAdoptive immunotherapyCell immunotherapyCellular immunotherapyCancer immunotherapyImmunotherapeutic approachesHLA compatibilityTumor microenvironmentAdult patientsImmunotherapyCombat cancerTumorMalignancyClonal cytopenia of undetermined significance: definitions, risk and therapeutic targets
Taborda C, Zeidan A, Mendez L. Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets. Frontiers In Hematology 2024, 3: 1419323. DOI: 10.3389/frhem.2024.1419323.Peer-Reviewed Original ResearchClonal hematopoiesis of indeterminate potentialClonal hematopoiesisClonal cytopeniaSomatic genetic alterationsTherapeutic targetStem/progenitor cell populationsRisk stratification toolBlood of individualsMyeloid malignanciesMyeloid neoplasmsHematologic malignanciesPotential therapeutic targetIndeterminate potentialRisk stratificationBlood countGenetic alterationsStratification toolClinical investigationNatural historyCell populationsCytopeniasMalignancyBloodRiskCytopenia(sAcute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome
Alhajahjeh A, Bewersdorf J, Bystrom R, Zeidan A, Shimony S, Stahl M. Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome. Leukemia & Lymphoma 2024, 65: 1541-1551. PMID: 38962996, DOI: 10.1080/10428194.2024.2367040.Peer-Reviewed Original ResearchAcute myeloid leukemiaIntensive chemotherapyHypomethylating agentsMyeloid leukemiaAllogeneic stem cell transplantationAcute myeloid leukemia casesAcute myeloid leukemia subtypesStem cell transplantationComplex hematological malignancyCurrent treatment modalitiesRare genetic anomalyCell transplantationHematologic malignanciesTreatment modalitiesClinical outcomesTreatment responseInv(3Genetic alterationsLeukemia developmentTreatment strategiesCellular processesGenetic anomaliesLeukemiaFusion geneClinical implicationsPrognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma
Shimer S, Allen O, Yang C, Canavan M, Westvold S, Kim N, Morillo J, Parker T, Wallace N, Smith C, Adelson K. Prognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma. Journal Of Palliative Medicine 2024, 27: 879-887. PMID: 38990245, DOI: 10.1089/jpm.2023.0530.Peer-Reviewed Original ResearchGoals of carePrognostic awarenessQuality of lifeIllness understandingPrognostic understandingMultiple myelomaHematologic malignanciesAcute leukemiaFaith-based responseInformed treatment choicesChi-square testCohort of patientsLikelihood ratio chi-square testMount Sinai HospitalTreatment goalsMM cohortSinai HospitalCarePatient populationTreatment choiceHospitalized patientsHematologistsAssess discordanceLeukemiaPatientsA phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation.
Al Malki M, Keyzner A, Suh H, Popat U, Gill S, Chen Y, Solh M, Gowda L, Buonomo E, Wang Y, Murray J, MacBeath G, Barton D, Chattopadhyay S, Reshef R. A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. Journal Of Clinical Oncology 2024, 42: tps2678-tps2678. DOI: 10.1200/jco.2024.42.16_suppl.tps2678.Peer-Reviewed Original ResearchHematopoietic cell transplantationMinimal residual diseaseEngineered T cell therapiesPatient hematopoietic cellsT-cell therapyMinor histocompatibility antigensHematopoietic cellsHLA-A*02:01Residual diseaseCell transplantationHematologic malignanciesPost-HCTT cellsHistocompatibility antigensTreatment armsCAR-T cell therapyAllogeneic hematopoietic cell transplantationHematopoietic cell transplant patientsPrevent disease relapseRelapse post-HCTDose-limiting toxicityDisease-free survivalEngineered T cellsHaploidentical donor transplantationSurrogate of efficacyRapid Metagenomic Sequencing (RaMSes) for Comprehensive Detection of Respiratory Pathogens in Patients With Hematologic Malignancy
Hensley M, Sayed K, Haidar G, Wang X, Benos P, Ito S, Im A, Geramita E, Dela Cruz C, Morris A, Kitsios G. Rapid Metagenomic Sequencing (RaMSes) for Comprehensive Detection of Respiratory Pathogens in Patients With Hematologic Malignancy. 2024, a2915-a2915. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2915.Peer-Reviewed Original ResearchAbstract CT160: A phase I trial to evaluate allogeneic NKG2DL-targeting chimeric antigen receptor-grafted γδ T cells in subjects with advanced solid tumors or hematological malignancies (the ANGELICA Trial)
Choo J, Tan W, Luk L, Zeng J, Soh T, Soon S, Lieow J, Wong C, Pang M, Bari S, Poon M, Koh L, Chng W, Jeyasekharan A, Tan L, Chan E, Sundar R. Abstract CT160: A phase I trial to evaluate allogeneic NKG2DL-targeting chimeric antigen receptor-grafted γδ T cells in subjects with advanced solid tumors or hematological malignancies (the ANGELICA Trial). Cancer Research 2024, 84: ct160-ct160. DOI: 10.1158/1538-7445.am2024-ct160.Peer-Reviewed Original ResearchAdoptive cellular therapyPhase I studyHematologic malignanciesSolid tumorsCellular infusionT cellsHealthy donorsAmerican Association for Cancer Research annual meetingsDose levelsRecommended phase 2 doseTreatment of hematological malignanciesPhase 2 dosePoor marrow functionSubcutaneous IL-2Treatment-refractory tumorsDose-limiting toxicityPeripheral blood mononuclear cellsPre-treated patientsT-cell therapyPre-clinical dataBlood mononuclear cellsT cell survivalEnrollment of patientsDiverse tissue originDose escalationCD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Pal S, Tran B, Haanen J, Hurwitz M, Sacher A, Tannir N, Budde L, Harrison S, Klobuch S, Patel S, Meza L, Dequeant M, Ma A, He Q, Williams L, Keegan A, Gurary E, Dar H, Karnik S, Guo C, Heath H, Yuen R, Morrow P, Agarwal N, Srour S. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. Cancer Discovery 2024, 14: of1-of14. PMID: 38583184, PMCID: PMC11215406, DOI: 10.1158/2159-8290.cd-24-0102.Peer-Reviewed Original ResearchClear cell renal cell carcinomaChimeric antigen receptorCAR-T cellsT-cell therapyCell renal cell carcinomaRenal cell carcinomaT cellsCell carcinomaSolid tumorsAllogeneic CAR-T cell therapyChimeric antigen receptor T cellsAdvanced clear cell renal cell carcinomaAllogeneic CAR-T cellsClinical trialsCAR-T cell productsCAR-T cell therapyTreatment of solid tumorsFirst-in-human clinical trialCAR-T constructsDose-limiting toxicityT cell productionNovel treatment optionsTreatment of clear cell renal cell carcinomaHematologic malignanciesAntigen receptorAssociation of Hospitalist Care and Outcomes for Patients Electively Admitted for Chemotherapy
Vaughn J, Morris J, Merl M, Gould Rothberg BE. Association of Hospitalist Care and Outcomes for Patients Electively Admitted for Chemotherapy. Journal Of Brown Hospital Medicine 2024, 3: 115906. PMID: 40026792, PMCID: PMC11864383, DOI: 10.56305/001c.115906.Peer-Reviewed Original ResearchLength of stayAnticancer therapyHematologic malignanciesHospitalist careBlood cell count recoveryTumor lysis syndromeQuality outcomesMean discharge timeEfficiency of careOutcomes of length of stayMixed linear regression modelsCount recoveryCare of patientsMethotrexate clearanceTherapy initiationTherapy regimenNo significant differenceTherapy administrationPatientsLinear regression modelsMean timeTherapySignificant differenceImprove qualityMalignancyA phase 2 trial of CD24Fc for prevention of graft-versus-host disease
Magenau J, Jaglowski S, Uberti J, Farag S, Riwes M, Pawarode A, Anand S, Ghosh M, Maciejewski J, Braun T, Devenport M, Lu S, Banerjee B, DaSilva C, Devine S, Zhang M, Burns L, Liu Y, Zheng P, Reddy P. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. Blood 2024, 143: 21-31. PMID: 37647633, PMCID: PMC10934299, DOI: 10.1182/blood.2023020250.Peer-Reviewed Original ResearchConceptsAcute graft-versus-host diseaseGraft-versus-host diseaseHematopoietic stem cell transplantationDose-limiting toxicityMUD hematopoietic stem cell transplantationGVHD-free survivalMultidose regimenMyeloablative conditioningHematologic malignanciesHuman leukocyte antigen-matched unrelated donorsPrevention of graft-versus-host diseaseAllogeneic hematopoietic stem cell transplantationCalcineurin inhibitor-based prophylaxisMatched controlsDose-escalation phaseSingle-dose regimensStem cell transplantationPhase 2 trialSustained drug exposureAssociated with higher ratesDamage-associated molecular patternsExpansion cohortDouble-blindPlacebo-controlledUnrelated donor
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply